The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

(Reuters) -French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Sanofi has announced that it will be expanding its respiratory vaccines pipeline by acquiring UK-based Vicebio for up to ...

Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory ...

Sanofi has moved to bolster its vaccines business by reaching a deal to buy London, UK-based biotech Vicebio, which was ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology ...

Last week, a US Food and Drug Administration (FDA) advisory committee (AdCom) voted against approval of Danish drugmaker ...

Paris: Sanofi has announced it has entered into an agreement to acquire Vicebio Ltd, a privately held biotechnology company ...